Who
Mark A. Prygocki Sr.
Director
Company insider
Files Form 4 as: Director, Verrica Pharmaceuticals; Director, Clarus Therapeutics Holdings; Director, Revance Therapeutics; President, Medicis Pharmaceutical.
In numbers
- Trades disclosed
- 79
- Buys
- 1
- Sells
- 3
- Bought
- $59K
- Sold
- $5.7M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 7 Feb 2006
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,384 at $0.00 | filing |
| 9 Jun 2022filed 13 Jun 2022 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,384 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | Clarus Therapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —4,805 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | Clarus Therapeutics Holdings | SEC FORM 4 Code A | —1,922 at $0.00 | filing |
| 12 Dec 2021filed 14 Dec 2021 | Clarus Therapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —9,610 at $0.00 | filing |
| 12 Dec 2021filed 14 Dec 2021 | Clarus Therapeutics Holdings | SEC FORM 4 Code A | —3,844 at $0.00 | filing |
| 10 Jun 2021filed 17 Jun 2021 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,109 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,834 at $0.00 | filing |
| 11 Jun 2020filed 12 Jun 2020 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,834 at $0.00 | filing |
| 12 Jun 2019filed 14 Jun 2019 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,834 at $0.00 | filing |
| 14 Jun 2018filed 18 Jun 2018 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,502 at $0.00 | filing |
| 5 May 2016filed 9 May 2016 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 7 May 2015filed 14 May 2015 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 12 May 2014filed 14 May 2014 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 11 Dec 2012filed 13 Dec 2012 | Medicis Pharmaceuticaloption or derivative | SEC FORM 4 Code D | $51K3,424 at $14.80 | filing |
| 11 Dec 2012filed 13 Dec 2012 | Medicis Pharmaceuticaloption or derivative | SEC FORM 4 Code D | $1.1M76,733 at $14.80 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.